Skip to navigation Skip to content

Atypical haemolytic uraemic syndrome (aHUS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051103

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised eculizumab and ravulizumab for patients with atypical haemolytic uraemic syndrome (aHUS).

aHUS and listing dates

aHUS is a rare and life-threatening immune condition that causes abnormal blood clots to form in small blood vessels in the kidneys.

Listing dates:

  • eculizumab - 1 December 2014
  • ravulizumab - 1 January 2024

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details, dosing schedule and treatment chart, item and restriction codes, the PBS schedule and the Services Australia website.

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Tier 0 technical support - self-sufficiency

Tier 1 technical support - Local Peer Support (LPS)

Written Authority Required Drugs